EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A

Dagmar M Hajducek, Oceana Sinkovic, Pierre Chelle iD, Alfonso Iorio iD, Andrea Edginton iD

Haemophilia · 2025

DOI: 10.1111/hae.70061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Dagmar M Hajducek und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Haemophilia treatment is costly and only 25% of patients receive adequate care. Although not optimal, Factor VIII (FVIII) low‐dose prophylaxis (LDP) may reduce annual joint bleeding rates. Understanding FVIII usage, collected through the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) platform, and its association with Gross National Income per capita (GNI) and Universal Health Coverage index (UHCI) may provide insights in global disparities.

Aims

To provide insights in FVIII use to advocate for LDP in low‐income countries by providing: (i) statistical summary of FVIII usage, LDP prevalence, GNI and UHCI in WAPPS‐Hemo in 2017–2023; (ii) estimation of the relationship between LDP probability ( P LDP ) and GNI/UHCI for children (≤12 years) and adults; (iii) exploratory comparison of pharmacokinetics (PKs) across LDP/non‐LDP.

Methods

Descriptive statistics/graphical summaries for (i) and (iii), mixed‐effects logistic regression for (ii).

Results

Data from 6223 severe haemophilia patients (ages 0.1–92 years) showed that 18% and 32% of countries used ≤1% LDP infusions in children and adults. LDP prevalence rose annually, peaking at 7% for children and 14% for adults. GNI was found lower in LDP‐prevalent countries in children. In both children and adults, P LDP demonstrated an inverse association with GNI and UHCI. PK outcomes were similar across LDP status, except potentially for plasma‐derived products in children, however limited by sample size.

Conclusion

Underrepresentation of low‐resource countries in WAPPS‐Hemo underscores the financial challenges in haemophilia treatment. The association between GNI/UHCI and P LDP suggests cost‐driven adoption of LDP in low‐resource settings, especially in children. PK outcomes average similarities may facilitate LDP‐usage in WAPPS‐Hemo. Trial Registration NCT02061072, NCT03533504 (ClinicalTrials.gov)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHumansChildAdolescentAdultCross-Sectional StudiesChild, PreschoolYoung AdultMiddle AgedMaleInfantAgedAged, 80 and overFemaleDatabases, Factual

Stichwörter der Autor:innen

Factor VIIIcross‐sectional studiesdeveloping countrieshaemophilia Aprophylaxis

Substanzen

Factor VIII

Autor:innen und Institutionen

  • School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
  • Faculty of Health Sciences, McMaster University, Waterloo, Ontario, Canada.

ORCID-Profile: Pierre Chelle, Alfonso Iorio, Andrea Edginton

Zitieren

APA

Hajducek, D. M., Sinkovic, O., Chelle, P., Iorio, A., & Edginton, A. (2025). A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.70061

Vancouver

Hajducek DM, Sinkovic O, Chelle P, Iorio A, Edginton A. A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A. Haemophilia. 2025. doi:10.1111/hae.70061

BibTeX
@article{Hajducek2025,
  author = {Hajducek, Dagmar M and Sinkovic, Oceana and Chelle, Pierre and Iorio, Alfonso and Edginton, Andrea},
  title = {A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70061}
}
Kostenlos starten →